Kerry Ruia
Nurse Practitioner · New Hartford, NYNPI 1356486526
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 804 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by AbbVie at 25.3% of the total. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 804 payments — averaging $14.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- GSK$1K
- Novo Nordisk$878
- Pfizer$699
- plus $3K from 31 others
What the payments were for
- Food & beverage$11,24499%
- Education$1591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 269 | $2,880 |
| AstraZeneca | 52 | $1,472 |
| Lilly USA, LLC | 94 | $1,136 |
| GSK | 71 | $1,031 |
| Novo Nordisk | 80 | $878 |
| Pfizer | 59 | $699 |
| Bayer | 24 | $644 |
| Johnson & Johnson | 29 | $512 |
| Astellas Pharma US Inc | 22 | $366 |
| Axsome Therapeutics, Inc. | 13 | $233 |
| Amarin Pharma, Inc. | 13 | $149 |
| Novartis | 7 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $130 |
| Merck | 6 | $129 |
| Boehringer Ingelheim | 6 | $119 |
| Kowa Pharmaceuticals America, Inc. | 5 | $103 |
| Abbott | 6 | $101 |
| Phathom Pharmaceuticals, Inc. | 5 | $71 |
| Amgen(2 entities) | 3 | $69 |
| Daiichi Sankyo Inc. | 3 | $65 |
| Esperion Therapeutics, Inc. | 2 | $48 |
| Verona Pharma, Inc. | 2 | $46 |
| Mylan Specialty L.p. | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| IBSA Pharma Inc. | 2 | $36 |
| Corcept Therapeutics | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Eisai Inc. | 1 | $25 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Exact Sciences | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Viatris Specialty LLC | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Smith+Nephew | 1 | $17 |
| Genentech USA, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,403 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 14 | $29,642 |
| EliquisApixaban | 28 | $25,359 |
| JardianceEmpagliflozin | 14 | $17,727 |
| FarxigaDapagliflozin Propanediol | 17 | $17,651 |
| XareltoRivaroxaban | 20 | $15,460 |
| VascepaIcosapent Ethyl | 11 | $10,503 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $8,805 |
| Lagevrio (Eua)Molnupiravir | 16 | $3,980 |
| Rosuvastatin Calcium | 136 | $3,248 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,886 |
| Levothyroxine Sodium | 115 | $2,752 |
| Omega-3 Acid Ethyl Esters | 14 | $1,763 |
| Metoprolol Succinate | 77 | $1,657 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 41 | $1,535 |
| Lansoprazole | 15 | $1,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $878 | $29,64214 claims |
| PfizerEliquis | $699 | $25,35928 claims |
| Boehringer IngelheimJardiance | $119 | $17,72714 claims |
| AstraZenecaFarxiga | $1,472 | $17,65117 claims |
| Johnson & JohnsonXarelto | $512 | $15,46020 claims |
| GSKTrelegy Ellipta | $1,031 | $8,80512 claims |
| MerckLagevrio (Eua) | $129 | $3,98016 claims |
| AbbVieSynthroid | $2,880 | $1,19915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.
Other nurse practitioner in New Hartford
- Michelle ChambroneNew Hartford$12K
- Patricia McGoldrickNew York$202K
- Michelle DartSyracuse$95K
- Susan KreppelWilliamsville$67K
- Kerry AhernEast Syracuse$55K
- Valerie StanleyAlbany$55K
- Jodi LogerfoNew York$48K
- Grace WlasowiczRochester$41K
- Melissa LevinElmhurst$34K
- Carla JungquistCanandaigua$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.